Get started
Revance Therapeutics, Inc.Revance Therapeutics, Inc.Revance Therapeutics, Inc.

Revance Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

RVNC chart


Full chart

RVNC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪321.52 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.92 USD
Net income (FY)
‪−323.99 M‬ USD
Revenue (FY)
‪234.04 M‬ USD
Shares float
‪95.30 M‬
Beta (1Y)
0.86

Employees


Employees (FY)
597
Change (1Y)
+63 +11.80%
Revenue / Employee (1Y)
‪392.03 K‬ USD
Net income / Employee (1Y)
‪−542.69 K‬ USD

About Revance Therapeutics, Inc.


Sector
Health Technology
CEO
Mark J. Foley
Headquarters
Nashville
Website
revance.com
Founded
1999
FIGI
BBG001J2MJH8
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RVNC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

RVNC highest yielding bonds


RVNC5133129
Revance Therapeutics, Inc. 1.75% 15-FEB-2027
Yield to maturity
5.09%
Maturity date
Feb 15, 2027

Explore more bonds 

Frequently Asked Questions


The current price of RVNC is 3.08 USD — it has increased by 0.33% in the past 24 hours. Watch Revance Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Revance Therapeutics, Inc. stocks are traded under the ticker RVNC.
RVNC stock hasn't changed in a week, the month change is a −19.79% fall, over the last year Revance Therapeutics, Inc. has showed a −64.10% decrease.
We've gathered analysts' opinions on Revance Therapeutics, Inc. future price: according to them, RVNC price has a max estimate of 6.60 USD and a min estimate of 3.00 USD. Watch RVNC chart and read a more detailed Revance Therapeutics, Inc. stock forecast: see what analysts think of Revance Therapeutics, Inc. and suggest that you do with its stocks.
RVNC reached its all-time high on Nov 11, 2015 with the price of 42.41 USD, and its all-time low was 2.30 USD and was reached on Jun 26, 2024. View more price dynamics on RVNC chart.
See other stocks reaching their highest and lowest prices.
RVNC stock is 0.33% volatile and has beta coefficient of 0.86. Track Revance Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Revance Therapeutics, Inc. there?
Yes, you can track Revance Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Revance Therapeutics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RVNC earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.27 USD resulting in a −37.54% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Revance Therapeutics, Inc. earnings.
Revance Therapeutics, Inc. revenue for the last quarter amounts to ‪59.88 M‬ USD, despite the estimated figure of ‪68.17 M‬ USD. In the next quarter, revenue is expected to reach ‪72.94 M‬ USD.
RVNC net income for the last quarter is ‪−38.12 M‬ USD, while the quarter before that showed ‪−37.47 M‬ USD of net income which accounts for −1.71% change. Track more Revance Therapeutics, Inc. financial stats to get the full picture.
No, RVNC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 597.00 employees. See our rating of the largest employees — is Revance Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Revance Therapeutics, Inc. EBITDA is ‪−159.93 M‬ USD, and current EBITDA margin is −88.46%. See more stats in Revance Therapeutics, Inc. financial statements.
Like other stocks, RVNC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Revance Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Revance Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Revance Therapeutics, Inc. stock shows the strong sell signal. See more of Revance Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.